注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Anthera Pharmaceuticals, Inc.(Anthera)是一家生物製藥公司,專注於開發和銷售用於治療炎症相關嚴重疾病(包括酶替代療法和自身免疫性疾病)的產品。該公司擁有兩個III期候選產品,liprotamase(也稱Sollpura)和blisibimod。Sollpura是一種用於治療胰臟外分泌功能不足(EPI)(常見於囊腫性纖維化及其他病症)患者的非豬研究性胰酶補充治療(PERT)產品。Blisibimod靶向B細胞激活因子(BAFF)。該公司已通過一系列B細胞介導的自身免疫疾病(包括紅斑性狼瘡(SLE)或狼瘡、IgA腎病及狼瘡性腎炎等)實驗評估BAFF。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Christopher S. Henney | 81 | 2005 | Independent Director |
David E. Thompson | 74 | 2005 | Independent Director |
Jeffrey Wagener | - | - | Member of Scientific Advisory Board |
David Wofsy | - | 2008 | Member of Scientific Advisory Board |
John Craig Thompson | 55 | 2016 | CEO & Director |
Michael Wilschanski | - | - | Member of Scientific Advisory Board |
Paul F. Truex | 53 | 2004 | Executive Chairman |
Michael W. Konstan | - | - | Member of Scientific Advisory Board |
Joan T. Merrill | - | - | Member of Scientific Advisory Board |
Philip T. Sager | 66 | 2014 | Independent Director |
Jonathan Barratt | - | - | Member of Scientific Advisory Board |
Brent V. Furse | 53 | 2016 | Independent Director |
Kenneth Kalunian | - | 2008 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核